Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

A new analysis of obesity guidelines suggests more evidence is needed to develop stronger guidelines for the transition ...

Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

When pediatric health experts name the most worrisome medical conditions plaguing young people today, obesity often tops the list. According to global statistics from the World Health Organization, ...

Discover expert tips from an obesity medicine doctor on effective and sustainable ways to approach weight loss for type 2 ...

Individuals with obesity developed related comorbidities earlier and more frequently than those with normal BMI, with musculoskeletal pain being the most common, a large cohort study finds.

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

A meta-analysis of 19 studies found that pediatric patients with hidradenitis suppurativa (HS) show an increased rate of ...

For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months ...

Adolescents face significant barriers to obesity medication access, despite a surge in prescriptions. Discover the ...